Stratagene, Max Planck, Molecular Devices, GE, Applied Biosystems, Qiagen, Bruker BioSciences, Oxford Gene Technology, Roche, German Research Ministry | GenomeWeb
Stratagene Expects 7 Percent Rise in Q4 Revenues;
Licenses microRNA Sequences from Max Planck
 
Stratagene last week said that it expects fourth-quarter revenue to be around $24.7 million, or 7 percent better than last year’s pro forma revenue of $23 million for the same period.
 
The uptick came largely from sales of the company’s QPCR products and reagents, which were up 7 percent, and from allergy diagnostics products, which were up 23 percent, Stratagene said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.